Job title: Head of Clinical Renal, Early CVRM
Uptal Patel is the Head of Clinical Renal and Senior Group Director in Early CVRM at AstraZeneca where he leads early clinical strategy and development for a wide range of therapies that address several kidney diseases. Previously, he led the kidney diseases domain at Gilead Sciences where he established the scientific vision and direction for novel kidney therapies, fostered external collaborations to complement internal R&D capabilities, and advanced clinical development programs. Prior to this as a faculty member at Duke University, he developed and applied strategies to improve detection and management of kidney disease in populations, as well as directed several multidisciplinary translational research efforts to elucidate the inter-relationships between kidney disease and cardiovascular disease. He attended medical school at UCSF and completed training at the University of Michigan in internal medicine, pediatrics, adult nephrology, pediatric nephrology, and health services research. He currently serves on the Board of Directors for the Kidney Health Initiative and as an Adjunct Professor at Duke.
Panel Discussion: Advantages & Disadvantages of Targeting Trials to Specific Orphan Indications Versus Larger Public Health Problems 1:45 pm
day: Day One
Panel Discussion: Demonstrating Opportunity in Renal to Support a Business Case: 9:30 am
day: Day One